BIOTON S.A.

As of June 30, 2026, BIOTON S.A. carries a market capitalization of 340.02M, placing it among publicly traded companies globally. Its enterprise value stands at 406.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BIOTON S.A.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, BIOTON S.A. has 85.86M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.29, and the price-to-book ratio stands at 0.59.

As of June 30, 2026, BIOTON S.A. trades at an EV/EBITDA multiple of 11.75 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 406.03M versus a market cap of 340.02M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BIOTON S.A. maintains a current ratio of 1.24, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.61, indicating elevated leverage, while an interest coverage ratio of 6.61 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BIOTON S.A. posted a negative return on equity (ROE) of -1.60, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.21, reflecting losses generated across the asset base. The company generates approximately 736,559.89 in revenue per employee across its workforce of 359.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.64 indicates how many times BIOTON S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BIOTON S.A. recorded 573,000.00 in income tax expense. The company reported a pretax loss of -8.74M and -9.31M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, BIOTON S.A.'s stock has declined approximately 13.95% over the past 52 weeks. The 50-day moving average sits at 3.75, while the 200-day moving average is 3.99.

Over the twelve months ended June 30, 2026, BIOTON S.A. generated 264.43M in revenue and converted that into -9.31M in net income, yielding earnings per share of -0.11. EBITDA reached 34.55M, while operating income came in at -3.39M.

As of June 30, 2026, BIOTON S.A. holds 1.29M in cash and equivalents against 67.30M in total debt, resulting in a net debt position of 46.80M. Total book value stands at 579.54M, with working capital of 30.97M providing operational flexibility.

BIOTON S.A. produced 11.94M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -18.23M in capital expenditures, free cash flow totaled -6.29M - equivalent to -0.07 per share.

Over the twelve months ended June 30, 2026, BIOTON S.A. posted a gross margin of 36.26, reflecting its pricing power and cost economics. The operating margin of -1.28 and net profit margin of -3.52 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.85: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.33, meaning BIOTON S.A. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

BIOTON S.A.'s most recent stock split took place on January 14, 2014 with a 100:1 split ratio.

As of June 30, 2026, BIOTON S.A. has an Altman Z-Score of -1.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.